S 3346

The Freedom to Heal Act of 2025 seeks to establish a special registration process under the Controlled Substances Act to facilitate the administration of investigational drugs (Schedule I) for patients participating in the Federal Right to Try law. This registration would require physicians to demonstrate specific qualifications, secure agreements from drug manufacturers, and adhere to strict guidelines regarding drug storage and administration. The Act also allows for supplemental notifications to request additional drug quantities and establishes rules for treating patients across multiple, closely controlled sites.